Viewpoint Molecular Targeting, LLC develops pharmaceutical drugs for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. Our novel image-guided therapies enable a personalized approach to select patients that can benefit most and to optimize treatment planning for our targeted therapies.

Our unique “theranostic” agents possess properties for both diagnostic imaging and therapy for cancer, personalizing the selection of patients and optimizing patient care. Viewpoint’s leading product is an image-guided therapy for skin cancer (MelanX™), a next-generation personalized medicine approach aimed at transforming the global metastatic melanoma treatment market.

Venture Information
Stage: 
Pre-Clinical
Technology or Science Area: 
Pharma
Market: 
Cancer Diagnostics and Therapies
Company Information
Founders: 
Michael Schultz, Ph.D.
Frances Johnson, MD